Medical Affairs Reputations: Rheumatoid Arthritis (EU5) 2019

Detailed product-level analysis for benchmarking and improving the performance of medical affairs teams in the EU5

• How successful are medical affairs teams in meeting physicians’ needs?
• What medical affairs services and support do physicians value most?
• For which rheumatoid arthritis brands are medical affairs teams delivering services successfully?
• For which rheumatoid arthritis brands are medical affairs services falling short and where is there scope for improvement?

Clinicians treating rheumatoid arthritis need the ongoing support of medical affairs teams to ensure complete knowledge of a product’s clinical value and use. The quality of a medical affairs team’s response and service is critical in supporting prescribing and treatment decisions, so how do front-line physicians rate the service they get and where do they see room for improvement?

This and other key questions are answered in this insightful July 2019 analysis of 12 leading rheumatoid arthritis brands. Based on the results of an in-depth survey of 150 EU5-based rheumatologists, Medical Affairs Reputations (EU5) Rheumatoid Arthritis identifies the drivers that build clinician satisfaction and brand loyalty.

Medical affairs teams from leading companies in rheumatoid arthritis assessed

• AbbVie
• Biogen
• Bristol-Myers Squibb
• Eli Lilly
• Merck Sharp & Dohme
• Pfizer
• Roche
• Sanofi
• UCB

Leading brands covered in this report

• Benepali (etanercept; Biogen)
• Cimzia (certolizumab pegol; UCB)
• Enbrel (etanercept; Pfizer)
• Humira (adalimumab; AbbVie)
• Kevzara (sarilumab; Sanofi)
• MabThera (rituximab; Roche)
• Olumiant (baricitinib, Eli Lilly)
• Orencia (abatacept; Bristol-Myers Squibb)
• Remicade (infliximab; Merck Sharp & Dohme)
• RoActemra (tocilizumab; Roche)
• Simponi (golimumab; Merck Sharp & Dohme)
• Xeljanz (tofacitinib; Pfizer)

Answering important medical affairs performance questions

• What underpins the overall rankings of interaction quality for Humira, Olumiant and Xeljanz?
• What medical affairs services are most used by physicians?
• How frequently are physicians contacted by medical affairs teams working on Orencia, Enbrel and Remicade?
• How satisfied are physicians with the information provided on the clinical value of a product in comparison with its competitors?
• How do physicians prefer to interact and how frequently?
• Providing unbiased scientific information? Clinical trial updates? Answering medical enquiries? What are the services and attributes most valued by physicians for Benepali, Cimzia, RoActemra and Simponi?

 Exclusive to FirstView, Medical Affairs Reputations surveys reveal, at a brand level, physician satisfaction with the medical affairs services they receive and the key areas where teams can improve their performance

The experience of the physicians surveyed

This detailed analysis is based on a survey of 150 EU5 dermatologists and rheumatologists with a wealth of experience treating rheumatoid arthritis. On average they:

• See 91 rheumatoid arthritis patients in a typical month
• Have 19 years in practice
• Spend 88% of their time on direct patient care

This report gives you...

• Practical data to understand how rheumatologists rank the performance of medical affairs teams in rheumatoid arthritis
• 39 clear, easy to read charts that provide at-a-glance understanding of the survey findings
• Actionable and detailed information identifying the specific areas where medical affairs teams can improve their support and engagement with physicians

Why FirstView has an edge in pharmaceutical market research

FirstView research draws on LiMA (Leaders in Medicine Atlas), the world's largest directory of 3.5 million vetted and verified physicians. This proprietary physician research platform uses advanced big data capture, processing and analytics powered by AI and machine learning to ensure the most robust samples are used for every FirstView survey.

Other RHEUMATOID ARTHRITIS reports available

Medical Affairs Reputations US: Rheumatoid Arthritis

Market Access Impact US: Rheumatoid Arthritis

Market Access Impact Europe: Rheumatoid Arthritis

NPS+ US: Rheumatoid Arthritis

NPS+ Europe: Rheumatoid Arthritis

To learn about our cost effective Rheumatoid Arthritis intelligence package of all reports, please contact us at info@fwreports.com